Literature DB >> 3137316

Evaluation of treatment response to radiotherapy in head and neck cancer with fluorine-18 fluorodeoxyglucose.

H Minn1, R Paul, A Ahonen.   

Abstract

Nineteen patients with malignant head and neck tumors were imaged before and during radiation therapy with 18F-2-fluoro-2-deoxy-D-glucose (FDG) to study the effect of radiotherapy (RT) on FDG uptake. All tumor images were FDG-positive before treatment. After RT, a decrement of tumor FDG uptake was found in all but two patients; these were nonradioresponders. There was a significant decrement (p less than 0.001) in uptake ratios after irradiation of 30 +/- 5 Gy among the radioresponsive (CR + PR) but not among the radioresistant (NC + PD) tumors. The administered dose of RT correlated (r = 0.47, p less than 0.05) with the decrement in FDG activity among the CR + PR but not among the NC + PD patients. The biologic half-life of FDG radioactivity in tumor tissue was evaluated by dynamic scintigraphy. A change in the half-life of FDG toward the value observed in normal tissue was associated with treatment response. The results suggest that FDG imaging can be used for follow-up of RT in patients with head and neck cancer.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3137316

Source DB:  PubMed          Journal:  J Nucl Med        ISSN: 0161-5505            Impact factor:   10.057


  18 in total

1.  Cancer treatment monitoring with fluorine-18 2-fluoro-2-deoxy-D-glucose and positron emission tomography: frustration or future.

Authors:  H Minn; R Paul
Journal:  Eur J Nucl Med       Date:  1992

2.  Iliac lymph node metastasis of an unknown primary tumor: report of a case.

Authors:  Satoru Matsuyama; Yuji Nakafusa; Masayuki Tanaka; Yukie Yoda; Daisuke Mori; Kohji Miyazaki
Journal:  Surg Today       Date:  2006       Impact factor: 2.549

3.  FDG-PET in infectious lesions: The detection and assessment of lesion activity.

Authors:  Y Ichiya; Y Kuwabara; M Sasaki; T Yoshida; Y Akashi; S Murayama; K Nakamura; T Fukumura; K Masuda
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

4.  A clinical evaluation of FDG-PET to assess the response in radiation therapy for bronchogenic carcinoma.

Authors:  Y Ichiya; Y Kuwabara; M Sasaki; T Yoshida; J Omagari; Y Akashi; A Kawashima; T Fukumura; K Masuda
Journal:  Ann Nucl Med       Date:  1996-05       Impact factor: 2.668

Review 5.  Positron Emission Tomography (PET) in Oncology.

Authors:  Andrea Gallamini; Colette Zwarthoed; Anna Borra
Journal:  Cancers (Basel)       Date:  2014-09-29       Impact factor: 6.639

Review 6.  Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.

Authors:  P Rigo; P Paulus; B J Kaschten; R Hustinx; T Bury; G Jerusalem; T Benoit; J Foidart-Willems
Journal:  Eur J Nucl Med       Date:  1996-12

7.  Detection of cancer recurrence in irradiated mandible using positron emission tomography.

Authors:  H Minn; K Aitasalo; R P Happonen
Journal:  Eur Arch Otorhinolaryngol       Date:  1993       Impact factor: 2.503

8.  18-FDG PET in the diagnosis of laterocervical metastases from occult carcinoma.

Authors:  Davide Padovani; Claudia Aimoni; Pietro Zucchetta; Alessandro Paluzzi; Antonio Pastore
Journal:  Eur Arch Otorhinolaryngol       Date:  2008-06-28       Impact factor: 2.503

9.  Evaluation of the treatment response of lung cancer with positron emission tomography and L-[methyl-11C]methionine: a preliminary study.

Authors:  K Kubota; S Yamada; K Ishiwata; M Ito; T Fujiwara; H Fukuda; M Tada; T Ido
Journal:  Eur J Nucl Med       Date:  1993-06

10.  Biodistribution of the radionuclides (18)F-FDG, (11)C-methionine, (11)C-PK11195, and (68)Ga-citrate in domestic juvenile female pigs and morphological and molecular imaging of the tracers in hematogenously disseminated Staphylococcus aureus lesions.

Authors:  Pia Afzelius; Ole L Nielsen; Aage Ko Alstrup; Dirk Bender; Páll S Leifsson; Svend B Jensen; Henrik C Schønheyder
Journal:  Am J Nucl Med Mol Imaging       Date:  2016-01-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.